Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
53
PCLOF Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
-5.4%
Day range:
$0.04 - $0.04
52-week range:
$0.00 - $0.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.11x
P/B ratio:
--
Volume:
92.2K
Avg. volume:
17.5K
1-year change:
11.5%
Market cap:
$11.8M
Revenue:
$2.3M
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PCLOF
PharmaCielo Ltd.
|
-- | -- | -- | -- | -- |
|
ACHV
Achieve Life Sciences, Inc.
|
-- | -$0.28 | -- | -22.76% | $15.38 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 24.77% | 2133.71% | $16.67 |
|
INSD
Instadose Pharma Corp.
|
-- | -- | -- | -- | -- |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.06 | -- | -13.85% | $5.55 |
|
VERO
Venus Concept, Inc.
|
$14.5M | -$0.92 | -3.5% | -54.23% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PCLOF
PharmaCielo Ltd.
|
$0.06 | -- | $11.8M | -- | $0.00 | 0% | 5.11x |
|
ACHV
Achieve Life Sciences, Inc.
|
$4.97 | $15.38 | $264.6M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.35 | $16.67 | $2B | 27.36x | $0.00 | 0% | 8.15x |
|
INSD
Instadose Pharma Corp.
|
$0.0001 | -- | $53.2K | -- | $0.00 | 0% | -- |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.98 | $5.55 | $105.9M | -- | $0.00 | 0% | -- |
|
VERO
Venus Concept, Inc.
|
$1.52 | -- | $2.8M | -- | $0.00 | 0% | 0.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PCLOF
PharmaCielo Ltd.
|
618.37% | 0.588 | 294.91% | 0.04x |
|
ACHV
Achieve Life Sciences, Inc.
|
22.85% | 2.232 | 5.99% | 4.94x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.204 | 5.37% | 5.02x |
|
INSD
Instadose Pharma Corp.
|
-- | -105.598 | -- | -- |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.553 | 0.41% | 1.61x |
|
VERO
Venus Concept, Inc.
|
92.44% | 1.732 | 689.6% | 0.48x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PCLOF
PharmaCielo Ltd.
|
-$272.5K | -$1.8M | -62.27% | -1331.05% | -283.9% | -$2.6M |
|
ACHV
Achieve Life Sciences, Inc.
|
-$54K | -$14.7M | -139.57% | -189.88% | -- | -$11.3M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
INSD
Instadose Pharma Corp.
|
-- | -- | -- | -- | -- | -- |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
VERO
Venus Concept, Inc.
|
$8.8M | -$9.5M | -129.08% | -1236.95% | -68.93% | -$4.9M |
PharmaCielo Ltd. vs. Competitors
-
Which has Higher Returns PCLOF or ACHV?
Achieve Life Sciences, Inc. has a net margin of -155.88% compared to PharmaCielo Ltd.'s net margin of --. PharmaCielo Ltd.'s return on equity of -1331.05% beat Achieve Life Sciences, Inc.'s return on equity of -189.88%.
Company Gross Margin Earnings Per Share Invested Capital PCLOFPharmaCielo Ltd.-42.22% -$0.01 $2.1M ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M -
What do Analysts Say About PCLOF or ACHV?
PharmaCielo Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Achieve Life Sciences, Inc. has an analysts' consensus of $15.38 which suggests that it could grow by 209.36%. Given that Achieve Life Sciences, Inc. has higher upside potential than PharmaCielo Ltd., analysts believe Achieve Life Sciences, Inc. is more attractive than PharmaCielo Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PCLOFPharmaCielo Ltd.0 0 0 ACHVAchieve Life Sciences, Inc.5 0 0 -
Is PCLOF or ACHV More Risky?
PharmaCielo Ltd. has a beta of 0.898, which suggesting that the stock is 10.177% less volatile than S&P 500. In comparison Achieve Life Sciences, Inc. has a beta of 1.715, suggesting its more volatile than the S&P 500 by 71.456%.
-
Which is a Better Dividend Stock PCLOF or ACHV?
PharmaCielo Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Achieve Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCielo Ltd. pays -- of its earnings as a dividend. Achieve Life Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCLOF or ACHV?
PharmaCielo Ltd. quarterly revenues are $645.5K, which are larger than Achieve Life Sciences, Inc. quarterly revenues of --. PharmaCielo Ltd.'s net income of -$1M is higher than Achieve Life Sciences, Inc.'s net income of -$14.4M. Notably, PharmaCielo Ltd.'s price-to-earnings ratio is -- while Achieve Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCielo Ltd. is 5.11x versus -- for Achieve Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCLOFPharmaCielo Ltd.5.11x -- $645.5K -$1M ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M
-
Which has Higher Returns PCLOF or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -155.88% compared to PharmaCielo Ltd.'s net margin of 42.95%. PharmaCielo Ltd.'s return on equity of -1331.05% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital PCLOFPharmaCielo Ltd.-42.22% -$0.01 $2.1M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About PCLOF or AUPH?
PharmaCielo Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 8.58%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than PharmaCielo Ltd., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than PharmaCielo Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PCLOFPharmaCielo Ltd.0 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is PCLOF or AUPH More Risky?
PharmaCielo Ltd. has a beta of 0.898, which suggesting that the stock is 10.177% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.187%.
-
Which is a Better Dividend Stock PCLOF or AUPH?
PharmaCielo Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCielo Ltd. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCLOF or AUPH?
PharmaCielo Ltd. quarterly revenues are $645.5K, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. PharmaCielo Ltd.'s net income of -$1M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, PharmaCielo Ltd.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCielo Ltd. is 5.11x versus 8.15x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCLOFPharmaCielo Ltd.5.11x -- $645.5K -$1M AUPHAurinia Pharmaceuticals, Inc.8.15x 27.36x $73.5M $31.6M
-
Which has Higher Returns PCLOF or INSD?
Instadose Pharma Corp. has a net margin of -155.88% compared to PharmaCielo Ltd.'s net margin of --. PharmaCielo Ltd.'s return on equity of -1331.05% beat Instadose Pharma Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PCLOFPharmaCielo Ltd.-42.22% -$0.01 $2.1M INSDInstadose Pharma Corp.-- -- -- -
What do Analysts Say About PCLOF or INSD?
PharmaCielo Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Instadose Pharma Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that PharmaCielo Ltd. has higher upside potential than Instadose Pharma Corp., analysts believe PharmaCielo Ltd. is more attractive than Instadose Pharma Corp..
Company Buy Ratings Hold Ratings Sell Ratings PCLOFPharmaCielo Ltd.0 0 0 INSDInstadose Pharma Corp.0 0 0 -
Is PCLOF or INSD More Risky?
PharmaCielo Ltd. has a beta of 0.898, which suggesting that the stock is 10.177% less volatile than S&P 500. In comparison Instadose Pharma Corp. has a beta of -710.445, suggesting its less volatile than the S&P 500 by 71144.541%.
-
Which is a Better Dividend Stock PCLOF or INSD?
PharmaCielo Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instadose Pharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCielo Ltd. pays -- of its earnings as a dividend. Instadose Pharma Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCLOF or INSD?
PharmaCielo Ltd. quarterly revenues are $645.5K, which are larger than Instadose Pharma Corp. quarterly revenues of --. PharmaCielo Ltd.'s net income of -$1M is higher than Instadose Pharma Corp.'s net income of --. Notably, PharmaCielo Ltd.'s price-to-earnings ratio is -- while Instadose Pharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCielo Ltd. is 5.11x versus -- for Instadose Pharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCLOFPharmaCielo Ltd.5.11x -- $645.5K -$1M INSDInstadose Pharma Corp.-- -- -- --
-
Which has Higher Returns PCLOF or ONCY?
Oncolytics Biotech, Inc. has a net margin of -155.88% compared to PharmaCielo Ltd.'s net margin of --. PharmaCielo Ltd.'s return on equity of -1331.05% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital PCLOFPharmaCielo Ltd.-42.22% -$0.01 $2.1M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About PCLOF or ONCY?
PharmaCielo Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 464.3%. Given that Oncolytics Biotech, Inc. has higher upside potential than PharmaCielo Ltd., analysts believe Oncolytics Biotech, Inc. is more attractive than PharmaCielo Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PCLOFPharmaCielo Ltd.0 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is PCLOF or ONCY More Risky?
PharmaCielo Ltd. has a beta of 0.898, which suggesting that the stock is 10.177% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.717%.
-
Which is a Better Dividend Stock PCLOF or ONCY?
PharmaCielo Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCielo Ltd. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCLOF or ONCY?
PharmaCielo Ltd. quarterly revenues are $645.5K, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. PharmaCielo Ltd.'s net income of -$1M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, PharmaCielo Ltd.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCielo Ltd. is 5.11x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCLOFPharmaCielo Ltd.5.11x -- $645.5K -$1M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns PCLOF or VERO?
Venus Concept, Inc. has a net margin of -155.88% compared to PharmaCielo Ltd.'s net margin of -163.68%. PharmaCielo Ltd.'s return on equity of -1331.05% beat Venus Concept, Inc.'s return on equity of -1236.95%.
Company Gross Margin Earnings Per Share Invested Capital PCLOFPharmaCielo Ltd.-42.22% -$0.01 $2.1M VEROVenus Concept, Inc.64% -$12.14 $35.8M -
What do Analysts Say About PCLOF or VERO?
PharmaCielo Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 7571.05%. Given that Venus Concept, Inc. has higher upside potential than PharmaCielo Ltd., analysts believe Venus Concept, Inc. is more attractive than PharmaCielo Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PCLOFPharmaCielo Ltd.0 0 0 VEROVenus Concept, Inc.0 1 0 -
Is PCLOF or VERO More Risky?
PharmaCielo Ltd. has a beta of 0.898, which suggesting that the stock is 10.177% less volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.041, suggesting its less volatile than the S&P 500 by 104.127%.
-
Which is a Better Dividend Stock PCLOF or VERO?
PharmaCielo Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCielo Ltd. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCLOF or VERO?
PharmaCielo Ltd. quarterly revenues are $645.5K, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. PharmaCielo Ltd.'s net income of -$1M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, PharmaCielo Ltd.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCielo Ltd. is 5.11x versus 0.03x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCLOFPharmaCielo Ltd.5.11x -- $645.5K -$1M VEROVenus Concept, Inc.0.03x -- $13.8M -$22.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
BIDU alert for Jan 5
Baidu, Inc. [BIDU] is down 0.42% over the past day.
Buy
69
KORU alert for Jan 5
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 23.79% over the past day.
Buy
62
BE alert for Jan 5
Bloom Energy Corp. [BE] is up 19.51% over the past day.
